Table 6 Stratification of clinical T stage of the detectable prostate cancers according to subgrouping of PSA level
PSA (ng/ml) | No. of PC | T1 | T2 | T3 | T4 |
|---|---|---|---|---|---|
0–4 | 21 | 4 (19.0%) | 11 (52.4%) | 6 (28.6%) | 0 (0.0%) |
4–10 | 61 | 2 (3.3%) | 18 (29.5%) | 23 (37.7%) | 18 (29.5%) |
10–20 | 123 | 12 (9.8%) | 25 (20.3%) | 38 (30.9%) | 48 (39.0%) |
20–100 | 146 | 8 (5.5%) | 36 (24.6%) | 43 (29.5%) | 59 (40.4%) |
≥ 100 | 87 | 0 (0.0%) | 7 (8.0%) | 29 (33.3%) | 51 (58.7%) |
Total | 438 | 26 (6.0%) | 97 (22.1%) | 139 (31.7%) | 176 (40.2%) |